Literature DB >> 15599731

Can body volume be determined by PET?

Michael Hentschel1, Dominik Paul, Ulrike Korsten-Reck, Michael Mix, Frank Müller, Stefan Merk, Ernst Moser, Ingo Brink.   

Abstract

PURPOSE: To avoid dependence on body weight, the standardised uptake value (SUV) in positron emission tomography (PET) can instead be normalised to the lean body mass (LBM), which can be determined from body volume and mass. This study was designed to answer the following questions: Firstly, can the total body volume in principle be determined using PET? Secondly, is the precision of this measurement comparable to that achieved using an established standard method.
METHODS: Ten patients were examined during oncological whole-body PET examinations. The whole-body volume of the patients was determined from the transmission scan in PET. Air displacement plethysmography with BOD POD was used for comparison as the standard method of volume determination.
RESULTS: In all patients, the whole-body volumes could be determined using PET and the standard method. Bland and Altman [23] analysis for agreement between the volumes determined by the two methods (presentation of differences vs means) revealed a very small difference of -0.14 l. With a mean patient volume of 71.81+/-15.93 l, the relative systematic error is only <0.1%. On this basis, equality of the volume values determined by the two methods can be assumed.
CONCLUSION: PET can be used as a supplementary method for experimental determination of whole-body volume and total body fat in tumour patients. The fat content can be used to calculate the LBM and to determine body weight-independent SUVs (SUV(LBM)).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599731     DOI: 10.1007/s00259-004-1714-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  Lean body mass-based standardized uptake value, derived from a predictive equation, might be misleading in PET studies.

Authors:  Taner Erselcan; Bulent Turgut; Derya Dogan; Semra Ozdemir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-10       Impact factor: 9.236

2.  Lean body mass; its clinical significance and estimation from excess fat and total body water determinations.

Authors:  A R BEHNKE; E F OSSERMAN; W C WELHAM
Journal:  AMA Arch Intern Med       Date:  1953-05

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Assessment of abdominal fat content by computed tomography.

Authors:  G A Borkan; S G Gerzof; A H Robbins; D E Hults; C K Silbert; J E Silbert
Journal:  Am J Clin Nutr       Date:  1982-07       Impact factor: 7.045

5.  Validity of methods of body composition assessment in young and older men and women.

Authors:  J L Clasey; J A Kanaley; L Wideman; S B Heymsfield; C D Teates; M E Gutgesell; M O Thorner; M L Hartman; A Weltman
Journal:  J Appl Physiol (1985)       Date:  1999-05

6.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.

Authors:  H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

7.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

8.  Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs?

Authors:  M Löffler; M Weckesser; Ch Franzius; D Nashan; O Schober
Journal:  Nuklearmedizin       Date:  2003-08       Impact factor: 1.379

Review 9.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

10.  Clinical use of the hyperthermia treatment planning system HyperPlan to predict effectiveness and toxicity.

Authors:  Geetha Sreenivasa; Johanna Gellermann; Beate Rau; Jacek Nadobny; Peter Schlag; Peter Deuflhard; Roland Felix; Peter Wust
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.